FY2028 Earnings Estimate for 2seventy bio, Inc. (NASDAQ:TSVT) Issued By Leerink Partnrs

2seventy bio, Inc. (NASDAQ:TSVT - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2028 earnings estimates for shares of 2seventy bio in a report released on Sunday, April 7th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of $2.52 for the year, up from their prior estimate of $2.50. Leerink Partnrs currently has a "Outperform" rating on the stock. The consensus estimate for 2seventy bio's current full-year earnings is ($1.36) per share.

Several other equities research analysts also recently commented on TSVT. SVB Leerink upgraded shares of 2seventy bio from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $5.00 to $18.00 in a research report on Wednesday, January 31st. TD Cowen restated a "market perform" rating on shares of 2seventy bio in a research report on Wednesday, January 31st. Citigroup boosted their price target on shares of 2seventy bio from $9.00 to $12.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Wedbush reiterated a "neutral" rating and issued a $5.00 price objective on shares of 2seventy bio in a research note on Monday, March 18th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $13.17.

2seventy bio Trading Up 2.2 %

NASDAQ:TSVT traded up $0.12 during mid-day trading on Tuesday, hitting $5.63. 1,351,223 shares of the company's stock were exchanged, compared to its average volume of 1,481,031. The company has a 50 day simple moving average of $5.23 and a 200-day simple moving average of $3.93. 2seventy bio has a fifty-two week low of $1.53 and a fifty-two week high of $12.69. The firm has a market capitalization of $288.88 million, a P/E ratio of -1.25 and a beta of 1.84.

2seventy bio (NASDAQ:TSVT - Get Free Report) last posted its earnings results on Tuesday, March 5th. The company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.11. 2seventy bio had a negative net margin of 216.73% and a negative return on equity of 59.19%. The business had revenue of $10.68 million for the quarter, compared to the consensus estimate of $13.91 million. During the same period last year, the company earned ($0.60) EPS.

Institutional Trading of 2seventy bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY bought a new stake in 2seventy bio during the 1st quarter valued at $25,000. US Bancorp DE boosted its holdings in shares of 2seventy bio by 754.1% in the 2nd quarter. US Bancorp DE now owns 2,528 shares of the company's stock worth $26,000 after buying an additional 2,232 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new position in shares of 2seventy bio in the 1st quarter worth about $30,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of 2seventy bio in the 2nd quarter worth about $33,000. Finally, Diversified Trust Co purchased a new position in shares of 2seventy bio in the 3rd quarter worth about $41,000. Institutional investors own 93.90% of the company's stock.

Insider Buying and Selling at 2seventy bio

In other 2seventy bio news, Director Casdin Capital, Llc purchased 330,000 shares of the firm's stock in a transaction on Monday, March 25th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $1,673,100.00. Following the purchase, the director now owns 1,960,000 shares of the company's stock, valued at approximately $9,937,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.60% of the stock is currently owned by company insiders.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.